



(51) International Patent Classification:

A61K 38/17 (2006.01) A61P 35/00 (2006.01)
C07K 16/40 (2006.01) A61P 37/00 (2006.01)
C07K 16/28 (2006.01)

(21) International Application Number:

PCT/US2022/077663

(22) International Filing Date:

06 October 2022 (06.10.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/253,211 07 October 2021 (07.10.2021) US

(71) Applicant: OMEROS CORPORATION [US/US]; 201 Elliott Avenue West, Seattle, WA 98119 (US).

(72) Inventors: ALI, Mohammed, Youssif, Ibrahim; c/o Omeros Corporation, 201 Elliot Avenue West, Seattle, WA 98119 (US). DEMOPULOS, Gregory, A.; c/o Omeros Corporation, 201 Elliot Avenue West, Seattle, WA 98119 (US). DOULAMI, Christiana; c/o Omeros Corporation, 201 Elliot Avenue West, Seattle, WA 98119 (US). SCHWAEBLE, Hans-Wilhelm; c/o Omeros Corporation, 201 Elliot Avenue West, Seattle, WA 98119 (US). YABUKI,


Munehisa; c/o Omeros Corporation, 201 Elliot Avenue West, Seattle, WA 98119 (US).

(74) Agent: GERTZ, Glenda, A.; Omeros Corporation, 201 Elliott Avenue West, Seattle, WA 98119 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,

(54) Title: TARGETED CATALYTIC COMPLEMENT-ACTIVATING MOLECULES AND METHODS OF USE THEREOF

**FIG.41**

(57) Abstract: In one aspect, the present disclosure provides targeted complement-activating molecules comprising a target-binding domain and a complement-activating serine protease effector domain. In some embodiments, the target-binding domain is derived from an antibody or an antigen-binding fragment thereof. Also provided are compositions and methods for treating cancer, autoimmune disease, or microbial infection, including bacterial, viral, fungal, or parasitic infection, using targeted complement-activating molecules.

[Continued on next page]

SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*